Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Gynecologic 1

Conditions

Breast Neoplasms 4Endometrial Neoplasms 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Imlunestrant × Clear all
NCT05307705 2026-04-20

PIKASSO-01

Eli Lilly and Company

Phase 1 Active not recruiting
193 enrolled
Breast

Breast Neoplasms

NCT05509790 2026-04-13

A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer

Eli Lilly and Company

Phase 1 Active not recruiting
17 enrolled
Breast

Breast Neoplasms

NCT04647487 2025-11-12

EMBER-2

Eli Lilly and Company

Phase 1 Completed
87 enrolled 13 charts
Breast

Breast Neoplasms

NCT04188548 2025-06-04

EMBER

Eli Lilly and Company

Phase 1 Active not recruiting
500 enrolled
BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡